Cargando…

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge

INTRODUCTION: Ovarian cancer is a leading cause of death among women with gynecologic malignancies. The relapse rate is high after platinum-based therapy, with the effectiveness of subsequent treatment lines decreasing over time. Recent data suggest the benefit of maintenance therapy with niraparib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caeiro, Cláudia, Leão, Inês, Oliveira, Inês, Sousa, Isabel, André, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442551/ https://www.ncbi.nlm.nih.gov/pubmed/36063278 http://dx.doi.org/10.1007/s12325-022-02259-2

Ejemplares similares

BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
por: Wysham, Weiya Z., et al.
Publicado: (2012)

Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells
por: Chirshev, Evgeny, et al.
Publicado: (2021)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

The BRCAness Landscape of Cancer
por: Guo, Maoni, et al.
Publicado: (2022)

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations
por: Jorge, Soledad, et al.
Publicado: (2019)

The role of asymptomatic screening in the detection of recurrent ovarian cancer
por: Richardson, M.T., et al.
Publicado: (2020)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases
por: Cheng, Yuan, et al.
Publicado: (2018)

Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series
por: Matsuo, Koji, et al.
Publicado: (2018)

Optimal chemotherapy treatment for women with recurrent ovarian cancer
por: Fung-Kee-Fung, M., et al.
Publicado: (2007)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype
por: Jeong, Keun-Yeong, et al.
Publicado: (2021)

BRCAness as a prognostic indicator in patients with early breast cancer
por: Liu, Lei, et al.
Publicado: (2020)

Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer
por: Johns, E.A., et al.
Publicado: (2021)

Salvage treatment in recurrent endometrial cancer of the pelvis and peritoneal cavity
por: McAlarnen, Lindsey A., et al.
Publicado: (2019)

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis
por: Yin, Dan, et al.
Publicado: (2023)

Complete surgical resection of isolated recurrent high-grade epithelial ovarian cancer in highly selected patients without chemotherapy is associated with an excellent outcome
por: Boyles, Glenn P., et al.
Publicado: (2019)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
por: González Martín, A., et al.
Publicado: (2013)

Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness
por: Darbeheshti, Farzaneh, et al.
Publicado: (2022)

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor()
por: Summey, Rebekah M., et al.
Publicado: (2022)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
por: Lee, Elizabeth K., et al.
Publicado: (2020)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype
por: Tommasi, Stefania, et al.
Publicado: (2016)

Laparoscopic ovarian transposition prior to pelvic radiation for gynecologic cancer
por: Swift, Brenna E., et al.
Publicado: (2018)

Diaphragm hernia after debulking surgery in patients with ovarian cancer
por: Ehmann, Sarah, et al.
Publicado: (2021)

Transcatheter recanalization of chronic total occlusion in congenital heart disease: case reports and lessons from percutaneous coronary interventions
por: Hribernik, Ines, et al.
Publicado: (2023)

Retropupillary iris claw intraocular lens implantation in aphakia for dislocated intraocular lens
por: Faria, Mun Yueh, et al.
Publicado: (2016)

Fibromatosis of the breast; another diagnosis of cancer like lesions: About 4 cases reports
por: Mazhoud, Ines, et al.
Publicado: (2023)

Aspirin use correlates with survival in women with clear cell ovarian cancer
por: Wield, Alyssa M., et al.
Publicado: (2018)

Death of 43 Indonesian women with ovarian cancer: A case series
por: Mulawardhana, Pungky, et al.
Publicado: (2020)

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
por: Zhang, Honghong, et al.
Publicado: (2017)

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
por: Tutt, A
Publicado: (2018)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qak2tkb0q533br98398ht6m49c